Screener
Enliven Therapeutics ELVN Invested capital
Discontinued — last reported Q1 '26
Invested capital at other companies
Other financials
Where this comes from
Calculated from Enliven Therapeutics’s reported figures.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
FAQ
- What is Enliven Therapeutics's invested capital?
- Enliven Therapeutics (ELVN) reported invested capital of $321.48M in Q1 2026.
- How has Enliven Therapeutics's invested capital changed year-over-year?
- Enliven Therapeutics's invested capital increased by 71.6% year-over-year, from $187.29M to $321.48M.
- What is the long-term trend for Enliven Therapeutics's invested capital?
- Over 2 years (2021 to 2025), Enliven Therapeutics's invested capital has grown at a 99.7% compound annual growth rate (CAGR), from -$90.54M to $361.1M.
- What does invested capital mean?
- Total debt plus shareholders' equity minus cash, at the quarter end. The capital actually put to work in the operating business — the denominator of return on invested capital (ROIC).
Ask your AI about Enliven Therapeutics's invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude